← All trials
NCT05922436
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 15, 2023
- Primary completion
- May 24, 2024
- Completion date
- May 25, 2024
- First posted
- Jun 28, 2023
- Last posted
- Jun 28, 2023
- Enrollment
- 378
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Qilu Pharmaceutical Co., Ltd.Lead sponsor
- Shandong UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.